Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/7/2026

Empagliflozin (Jardiance) for Cardiorenal Protection in Patients with Reduced eGFR

Indications & Initiation Criteria

Dosing Recommendations

Pre‑Initiation Assessment

Monitoring & Follow‑Up

Safety‑Related Pitfalls (What to Avoid)

Evidence of Cardiovascular & Renal Benefit

Integration with Other CKD Therapies

Jardiance (Empagliflozin) GFR Thresholds for Cardiovascular and Renal Protection

Guideline-Based Approach

  • The American Diabetes Association recommends SGLT2 inhibitors, including empagliflozin, can be used down to eGFR ≥20 mL/min/1.73 m² for reducing CKD progression and cardiovascular events in patients with diabetes 3, 4
  • The American Diabetes Association suggests not using Jardiance for glucose lowering when eGFR <45 mL/min/1.73 m², as the glucose-lowering efficacy is significantly reduced due to its mechanism of action 4

Clinical Decision Algorithm

  • For patients with eGFR 30-44 mL/min/1.73 m², the American Diabetes Association supports continuation of Jardiance for cardiovascular and renal protection if the patient has heart failure, established cardiovascular disease, or albuminuria 3, 4
  • For patients with eGFR 20-29 mL/min/1.73 m², guidelines support continuation of Jardiance for cardiovascular and renal protection in patients already on therapy 3, 5

Practical Recommendation

  • The American Diabetes Association recommends following FDA labeling and discontinuing Jardiance at eGFR <45 mL/min/1.73 m² unless the patient has compelling cardiovascular or renal indications, in which case continuation down to eGFR 20 mL/min/1.73 m² is supported by strong guideline evidence 3, 4